



Investigational Device Exemption (IDE)

JH & JL

SUBMISSION CHECKLIST

Please type or print legibly the information below, print the form, and include it in your submission packet.

<input type="checkbox"/> JH Region (AR, CO, LA, MS, NM, OK, TX, & Indian Health Services & 04911)		<input type="checkbox"/> JL Region (DC, DE, MD, NJ, PA, & 12901)			
6-Digit IDE Study Number:	G	P	501(k)	I	Q
Requesting Approval for:	<input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> A & B		Clinical Trial 8-Digit Registration Number (NCT)		
Study Name:					
Participating Provider Facility/Hospital Name(s) & 6-Digit Provider Transaction Access Number (PTAN) (where procedure is to be performed)					
Hospital/Facility Name		PTAN	Hospital/Facility Name		PTAN
Participating Physician(s) and Sub-Physician(s) Name(s) and/or Group Name & 10-Digit National Provider Identifier (NPI) (For additional physicians please attach names on a separate sheet.)					
Physician Name(s)		NPI	Physician Name(s)		NPI
Contact Information List name of person submitting documents. Approval letter will be sent to contact below unless indicated elsewhere in documents.					
Title (Ms., Mr., etc.)	First and Last Name:				
Job Title:				Post-nominal initials Ex: RN	
Company Name:					
Department Name:					
Street:					
City:				State:	Zip:
Phone:			Extension:	Fax:	
Email:					
Signature of Principal Investigator (PI):			"Signed on behalf of" the Principle Investigator:		
★ Documents to Include in Submission Package ★				Fax to ☒	
<input type="checkbox"/> Completed Submission Checklist Form with either the Signature of the Primary Investigator or "Signed on behalf of" the Primary Investigator.				410-891-5231 Attn: JH IDE Applications or Attn: JL IDE Applications ★ If providing additional information, then please attach a cover page explaining the extra documents. For a complete list of submission documents please visit our website at: http://www.novitas-solutions.com	
<input type="checkbox"/> FDA Un-redacted/Unconditional Letter for IDE studies approved by FDA before 1/1/2015 <ul style="list-style-type: none"> • Cannot have any blackouts, whiteouts, or missing text. • Must have a signature page. • All FDA letters must be submitted by the Institution or person requesting approval, not a 3rd party representative, such as sponsor 					
<input type="checkbox"/> IRB Approval letter must show the Expiration Date					
<input type="checkbox"/> Informed Patient Consent which includes the Patient Signature page					
<input type="checkbox"/> Study Protocol or Summary which includes "Therapeutic Intent"					